WC
CARM

Wexford Capital’s Carisma Therapeutics CARM Stock Holding History

Wexford Capital’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,861
Closed -$34.2K – 214
2024
Q3 		$34.2K Buy
34,861
+15,000
+76% +$16.2K 0.01% 163
2024
Q2 		$30.2K Buy
+19,861
New +$29.6K 0.01% 181

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wexford Capital's CARM Position: Q4 2024 in Review

Wexford Capital sold out of Carisma Therapeutics (CARM) in Q4 2024, closing a stake of 34,861 shares — an estimated $34.2K sold.

Wexford Capital first reported a position in CARM in Q2 2024 and held it in 2 quarters. The position peaked at $34.2K in Q3 2024. 41 funds tracked by Wall St. Rank hold CARM as of Q4 2024.

  • Wexford Capital reported no remaining Carisma Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Wexford Capital sold 34,861 Carisma Therapeutics shares in Q4 2024, an estimated $34.2K.
  • Wexford Capital first reported a position in Carisma Therapeutics in Q2 2024 and held it in 2 quarters.
  • Wexford Capital's Carisma Therapeutics position peaked at $34.2K in Q3 2024.
  • 41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2024.

Based on Wexford Capital's 13F filing for Q4 2024, filed 14 Feb 2025.